Janssen Pharmaceutica
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 1953-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
16
Active:0
Completed:7
Trial Phases
2 Phases
Phase 3:2
Phase 4:4
Drug Approvals
1
PHILIPPINES:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 4
4 (66.7%)Phase 3
2 (33.3%)A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
Completed
- Conditions
- PsoriasisPlaque
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Janssen Pharmaceutica
- Target Recruit Count
- 1131
- Registration Number
- NCT02274363
An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Janssen Pharmaceutica
- Target Recruit Count
- 237
- Registration Number
- NCT01795898
An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2013-03-25
- Lead Sponsor
- Janssen Pharmaceutica
- Target Recruit Count
- 115
- Registration Number
- NCT01769339
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
Completed
- Conditions
- Pneumonia, BacterialNosocomial InfectionIntraabdominal InfectionsUrinary Tract Infection
- Interventions
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Janssen Pharmaceutica
- Target Recruit Count
- 170
- Registration Number
- NCT01763008
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Janssen Pharmaceutica
- Registration Number
- NCT01739491
- Prev
- 1
- 2
- 3
- 4
- Next
News
Contineum Therapeutics Completes Enrollment in Phase 2 Trial of PIPE-307 for Relapsing-Remitting Multiple Sclerosis
Contineum Therapeutics has completed enrollment of 168 patients in its Phase 2 VISTA trial evaluating PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).